Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
复制标题
DOI：
10.1016/j.lungcan.2011.03.009
复制
发表时间：
2011-11
期刊：
影响因子：
5.3
通讯作者：
Goodglick, Lee
中科院分区：
文献类型：
--
作者：
Mah, Vei;Marquez, Diana;Alavi, Mohammad;Maresh, Erin L.;Zhang, Li;Yoon, Nam;Horvath, Steve;Bagryanova, Lora;Fishbein, Michael C.;Chia, David;Pietras, Richard;Goodglick, Lee
雌激素信号通路可能在非小细胞肺癌（NSCLC）的发病机制中起重要作用，如芳香化酶和雌激素受体（ERα和ERβ）在许多这些肿瘤中的表达所证明的。在这里，我们检查是否ERα和ERβ水平与芳香化酶定义患者组的生存结果和可能的治疗方案。免疫组化进行了高密度组织芯片与所得数据和临床信息，为377例患者。患者按性别、年龄和肿瘤组织学进行细分，生存数据采用考克斯比例风险模型和Kaplan-Meier曲线确定。ERα或ERβ单独均不能预测NSCLC患者的生存率。然而，当与芳香化酶表达相结合时，较高的ERβ水平预示着肿瘤表达较高水平芳香化酶的患者的生存率较低。尽管这一发现在两种性别的患者中都存在，但在≥ 65岁的女性中尤其明显，ERβ和芳香化酶的高表达表明生存率明显低于单独使用芳香化酶的生存率。结论：ERβ和芳香化酶的表达对不同性别和年龄的NSCLC患者的生存有预测价值。这种预测值比单独的每个标记物更强。我们的研究结果表明，芳香化酶抑制剂单独或与雌激素受体调节剂联合治疗可能对这些患者的某些亚群有益。
Estrogen signaling pathways may play a significant role in the pathogenesis of non-small cell lung cancers (NSCLC) as evidenced by the expression of aromatase and estrogen receptors (ERα and ERβ) in many of these tumors. Here we examine whether ERα and ERβ levels in conjunction with aromatase define patient groups with respect to survival outcomes and possible treatment regimens. Immunohistochemistry was performed on a high-density tissue microarray with resulting data and clinical information available for 377 patients. Patients were subdivided by gender, age and tumor histology, and survival data was determined using the Cox proportional hazards model and Kaplan-Meier curves. Neither ERα nor ERβ alone were predictors of survival in NSCLC. However, when coupled with aromatase expression, higher ERβ levels predicted worse survival in patients whose tumors expressed higher levels of aromatase. Although this finding was present in patients of both genders, it was especially pronounced in women ≥ 65 years old, where higher expression of both ERβ and aromatase indicated a markedly worse survival rate than that determined by aromatase alone. Conclusion: Expression of ERβ together with aromatase has predictive value for survival in different gender and age subgroups of NSCLC patients. This predictive value is stronger than each individual marker alone. Our results suggest treatment with aromatase inhibitors alone or combined with estrogen receptor modulators may be of benefit in some subpopulations of these patients.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
11.2
作者：
Mah, Vei;Seligson, David B.;Goodglick, Lee
通讯作者：
Goodglick, Lee
影响因子：
4.8
作者：
Couse, JF;Lindzey, J;Korach, KS
通讯作者：
Korach, KS
影响因子：
5.8
作者：
Cappola, Anne R.;Ratcliffe, Sarah J.;Fried, Linda P.
通讯作者：
Fried, Linda P.
影响因子：
82.9
作者：
Kononen, J;Bubendorf, L;Kallioniemi, OP
通讯作者：
Kallioniemi, OP